Siddharth "Sid" H. Sheth | UNC Health

Dr. Siddharth Sheth, MD

Claim this profile

UNC Lineberger Comprehensive Cancer Center

Studies Oral Cancers
Studies Squamous Cell Carcinoma
5 reported clinical trials
13 drugs studied

Area of expertise

1

Oral Cancers

Siddharth Sheth, MD has run 2 trials for Oral Cancers. Some of their research focus areas include:

Stage IV
PD-L1 positive
HPV negative
2

Squamous Cell Carcinoma

Siddharth Sheth, MD has run 2 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

Stage IV
PD-L1 positive
HPV negative

Affiliated Hospitals

Image of trial facility.

UNC Lineberger Comprehensive Cancer Center

Image of trial facility.

University Of North Carolina At Chapel Hill

Clinical Trials Siddharth Sheth, MD is currently running

Image of trial facility.

Cetuximab + Pembrolizumab

for Head and Neck Cancer

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.

Recruiting

2 awards

Phase 3

16 criteria

Image of trial facility.

Immunotherapy +/− Targeted Therapy

for Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.

Recruiting

1 award

Phase 2

More about Siddharth Sheth, MD

Clinical Trial Related

1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Siddharth Sheth, MD has experience with

  • Pembrolizumab
  • Cetuximab
  • Durvalumab
  • Intensity Modulated Radiotherapy Treatments
  • Cisplatin
  • External Beam Radiotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Siddharth Sheth, MD specialize in?

Is Siddharth Sheth, MD currently recruiting for clinical trials?

Are there any treatments that Siddharth Sheth, MD has studied deeply?

What is the best way to schedule an appointment with Siddharth Sheth, MD?

What is the office address of Siddharth Sheth, MD?

Is there any support for travel costs?